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King Sau
osting by EAbstract Antihyperglycemic and hypolipidemic effects of ethanol extract of aerial parts ofMeloth-
ria maderaspatana and Coccinia indica were evaluated in STZ induced diabetes in Sprague–Dawley
rats. The rats were concurrently treated with 100 or 200 mg/kg b.w. p.o. for 14 days. The changes in
fasting blood glucose level and body weight were measured in 5 days interval. After 14 days exper-
imental period, rats were sacriﬁced by cervical decapitation, blood and liver samples were collected.
Biochemical estimation of plasma glucose, cholesterol, triglycerides, LDL, HDL, SGOT, SGPT and
ALP were done from blood sample. The liver glycogen content was estimated using standard pro-
cedure from homogenized liver sample. Administration of EEMm or EECi to STZ-diabetic rats
caused signiﬁcant antihyperglycemic and hypolipidemic effects (p< 0.001). The extracts were also
found to be signiﬁcantly effective (p< 0.001; p< 0.05) on recovery of altered biochemical param-
eters and decreased body weight in treated animals. Glibenclamide (0.5 mg/kg b.w.) was used as
standard in present study.
ª 2010 King Saud University. All rights reserved.1. Introduction
Diabetes mellitus (DM) has been deﬁned by a persistently ele-
vated blood glucose concentration, leading to complications9051237788.
m (A.K. Balaraman).
ity. All rights reserved. Peer-
d University.
lsevierthat can be acute and long term (Greenbaum and Harrison,
2008). Globally, DM presents enormous and increasingly
important public health issues. The prevalence of DM in all
age groups was estimated to be 2.8% (170 million) in 2000 and
the rate is expected to rise to 4.4% (366 million) in 2030 (Fons-
eca, 2006). The occurrence and consequences associated with
diabetes are found to be high in countries like India (31.7%),
China (20.8%) and USA (17.7%). The rate is expected to rise
to 79.4%, 42.3% and 30.3%, respectively, by 2030 in the above
countries (Wild et al., 2004). The worldwide survey on diabetes
reveals that among the entire diabetes cases more than 90% are
account to type-II (National Diabetes Fact sheet, 2005). The
overall death rate in people with diabetes is about twice that
of people without diabetes (Harrigan et al., 2001).
174 A.K. Balaraman et al.The beneﬁcial uses of medicinal plants in traditional system
of medicine of many cultures are extensively documented. Sev-
eral plants have been used as dietary adjuvant and in treating
the number of diseases even without any knowledge on their
proper functions and constituents. This practice may be attrib-
uted to the uncompromised cost and side effects of synthetic
hypoglycemic agents (Taylor and Triggle, 2006). Since antique
era, plants with medicinal properties are enormously used in
treating diabetes throughout the world. Many recent scientiﬁc
investigations have also conﬁrmed the efﬁcacy of plant prepa-
rations, few of which are remarkably effective (Marles and
Farnsworth, 1995).
Cucurbitaceae is a plant familywell known to have about 125
extant genera including 960 species. It is considered to be one of
the important families of plants with potent hypoglycemic ef-
fects (Bnouham et al., 2006). In modern drug discovery from
medicinal plants, the importance of cucurbitaceae species has
been markedly recognized in empirical control of DM. A signif-
icant number of species (Bryonia alba L., Citrullus colocynthis
(L), Schrad, Coccinia indica Wight et Arn., Cucumis sativus
L., Momordica charantia L., Momordica cymbalaria Hook.,
Momordica foetida Schumach. Et Thonn., Tricosanthes dioica
Roxb) in this family were reported to cause notable hypoglyce-
mic activity (Atta-Ur-Rahman and Zaman, 1989; Ivorra et al.,
1989; Marles and Farnsworth, 1995; Roman-Ramos et al.,
1995; Abdel-Hassan et al., 2000; Jayasooriya et al., 2000).
Melothria maderaspatana (Linn) Cogn. Syn.Mukia madera-
spatana, Cucumis maderaspatana or Mukia scabella (Family:
Cucurbitaceae) is a monoecious plant having scandent or pros-
trate stems, very hispid, leaves are variable in size, densely cov-
ered with white hairs. The plant is used as drug in the
compound preparation for chronic diseases, in which cough
is a predominant symptom (Kirtikar and Basu, 1975). Folklore
claims the plant as good diuretic, stomachic, gentle aperients,
antipyretic and anti-ﬂatulent (Nadkarani, 1971). It is widely
recommended in the southern part of Sri Lanka for alleviation
of various forms of liver disorders (Jayatilaka et al., 1990). M.
maderaspatana has also been reportedly found to exhibit anti
inﬂammatory (Ramakrishnamacharya et al., 1996) and anti-
cancer (Hussein and Kingston, 1982) activities. For the ﬁrst
time, extract of aerial parts of this plant was evaluated for anti-
diabetic and hypolipidemic effects.
C. indica (Cuccurbitaceae) is a creeper that grows wild and in
abundance inmajor parts of India. The plant has been used since
ancient times for treating diabetes mellitus in the Indian system
of medicine known as ayurveda. As it was signiﬁcantly effective
in diabetes treatment,C. indicawas described by some as ‘Indian
Substitute for Insulin’ (Chopra et al., 1958). The plant also
gained many reported scientiﬁc values as anti diabetic medicine
(Mukerjee et al., 1972; Venkatraman and Pari, 2002, 2003).
Because of the professed outcome, negligible side effects or
toxic contribution and comparatively cost effective than syn-
thetic drugs, herbal, speciﬁcally cucurbitaceae family plants
are widely advised choice of drug for diabetes even without
their scientiﬁc backgrounds. M. Maderaspatana is one of such
plants used in India for treating diabetes and liver disorders.
However, the scientiﬁc record on this plant is very poor than
C. indica. C. indica is the primary choice of plant as a drug
in diabetes treatment therefore, the present study was under-
taken to evaluate the antidiabetic and hypolipidemic effects
of extract of aerial partsM.Maderaspatana (which is unknown
for its antidiabetic activity) against STZ-diabetic rat model.The effectiveness of the plant was experimentally compared
toC. indica (a known potent antidiabetic plant in cucurbitaceae
family).2. Materials and methods
2.1. Plant material
Aerial parts of M. maderaspatana and C. indica were collected
from Koothiramedu village, Kanchipuram district (Tamil
Nadu, India) during the month of October–December. The
plant materials were authenticated by Prof. Jayaraman, Direc-
tor, National Institute of Herbal Science (PARC), Chennai.
The voucher specimens (Ref. No. PARC/2009/260 & 261) have
been kept there for future reference. The collected plant mate-
rials were washed; shade dried and pulverized using a mechan-
ical grinder. The powder materials were kept separately in an
air tight container till used further.
2.2. Chemicals
Streptozotocin (STZ) was purchased from Sigma chemical
company, Kolkata. All other chemicals used in the experi-
ments were purchased locally (Merck or SD ﬁne Chemicals)
and were of analytical grade.
2.3. Preparation of the extract
Pulverized aerial parts of M. maderaspatana or C. indica were
extracted by soaking in 95% ethanol with timely shaking and
stirring for 72 h (Maceration), and ﬁltered. The residue was
discarded and the ﬁltrate was concentrated in a rotary vacuum
evaporator at 50 C.
2.4. Maintenance of animals and approval of protocol
Adult male Sprague–Dawley rats (180–250 g) of either sex were
procured from theUniversity authorized supplier. Animals were
maintained in an air-conditioned room (24 ± 2 C) with rela-
tive humidity of 45–55% under a 12 h light/dark cycle. All ani-
mals had free access to standard diet and water ad libitum. The
whole experimental protocol was approved by the Institutional
Animal Ethics Committee and constituted in accordance with
rules and guidelines of the committee.
2.5. Induction of diabetes to test animals
The overnight fasted animals were induced to diabetics by a
single administration of STZ (50 mg/kg b.w. i.p.) in ice cold
citrate buffer (pH 7.4). The threshold level of fasting serum
glucose to diagnose diabetes was taken as >150 mg/dl and
only those animals were included in the study, rest are ex-
cluded from the study. The animals were divided into seven
groups of six in each group.
2.6. Effect of EEMm or EECi on serum glucose change in STZ-
diabetes in rats
A 15 days short term study was chosen to perform to check
the effect of M. maderaspatana or C. indica in STZ-diabetic
rats. Animals received extract for a period of 15 days after
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of drug or control was followed as below:
Groups Administrations
I Vehicle control rats (0.5% CMC solution)
II STZ induced diabetic rats (negative control)
III Diabetic rats treated with EEMm 100 mg/kg b.w./
day, p.o.
IV Diabetic rats treated with EEMm 200 mg/kg b.w./
day, p.o.
V Diabetic rats treated with EECi 100 mg/kg b.w./
day, p.o.
VI Diabetic rats treated with EECi 200 mg/kg b.w./
day, p.o.
VII Diabetic rats treated with Glibenclamide 0.5 mg/
kg b.w./day, p.oTable 1 Effec
Groups
Vehicle control
STZ control
EEMm
EEMm
EECi
EECi
Glibenclamide
Values are in me
a STZ induced
b Treated grou
# p< 0.001.
* p< 0.001.The fasting blood glucose levels and body weight of the ani-
mals were determined at 0, 5, 10 and 15 day of treatments.
Blood samples were collected from tail or retro-orbital vein.
2.7. Estimation of liver glycogen
After 15 days experimental period, the 12 h fasted rats were
sacriﬁced by cervical decapitation. The liver tissue (1 g) was
collected, placed in a centrifuge tube containing 2 ml of KOH
(300 g/L) after washing with saline water and heated for
20 min with occasional shaking. To this, a saturated solution
of sodium sulphate (0.2 ml) was added and mixed thoroughly.
The glycogen was precipitated by the addition of ethanol
(5 mL). The precipitate was removed and dissolved in 10 mL
of water. One milliliter of this solution was added to 1 mL of
HCl (1.2 mol/l) and boiled for 2 h. After 2 h, the solutions were
neutralized by NaOH (0.5 mol/l) using phenol red as indicator.
The neutralized solution was diluted to 5 ml and glycogen
content was determined. The glycogen content was expressed
as mg/g of liver tissue (Sadasivam andManickam, 1996; Seifter
et al., 1950).
2.8. Estimation of biochemical parameters
The blood was collected on day 15 after 12 h of last dose of
drug administration. Rats were anesthetized by intraperitonealt of ethanol extract of EEMm or EECi on serum glu
Dose (mg/kg b.w.) Plasma glucose con
0 day
– 103.5 ± 2.7
– 370.7 ± 7.1a,#
100 367.7 ± 6.2
200 358.0 ± 4.45
100 360.8 ± 5.09
200 365.0 ± 4.41
0.5 358.8 ± 5.21
an± SEM, 6 rats in each group. STZ (50 mg/kg b.w.) w
diabetic group vs. vehicle control group.
p vs. STZ induced group.injection (1 ml/kg, b.w.) of Pentothal sodium (50 mg/ml in nor-
mal saline). Blood was withdrawn from the retro-orbital plexus
using capillary (20 mm length · 0.8 mm diameter) and col-
lected in sample tubes containing EDTA (3 mg/ml). Plasma
was separated and total cholesterol (TC) (Deeg and Ziegen-
horn, 1983). Triglycerides (TG), Low density lipoprotein
(LDL), high density lipoprotein (HDL) (Buccolo and David,
1973), serum glutamic oxaloacetic transaminase (SGOT), ser-
um glutamic-pyruvic transaminase (SGPT) and alkaline phos-
phatase (ALP) (Reitman and Frankel, 1957) were estimated by
Auto-Analyzer (Accucare, Acculab-101) using the standard
enzymatic methods and assay kits procured from Accucare,
Lab-Care diagnostics (India) Pvt. Ltd.
3. Statistical analysis
All the data are expressed as the mean ± SEM. The statistical
analysis was carried out by using Graph Pad Insat version 5.
The obtained results are analyzed by ANOVA followed by
post test (Bonferroni; one way and two way) and signiﬁcant
levels are p> 0.05, p> 0.01, p> 0.001.
4. Results
Tables 1 and 2 demonstrate the level of blood glucose and
changes in body weight of experimental rats at ﬁrst day
and at the end of the 5, 10 and 15 days of treatment. There
was signiﬁcant increase in the plasma glucose level and a sig-
niﬁcant decrease in body weight in diabetic rats. The admin-
istration of EEMm or EECi to diabetic rats resulted in a
signiﬁcant decrease in level of blood glucose level and a sig-
niﬁcant dose dependant increase in the body weight of rats.
The extract treated groups remained to have higher serum
glucose level throughout the experimental period when com-
pared with normal rats. The administration of EEMm or
EECi at the dose of 200 mg/kg b.w. showed a highly signiﬁ-
cant effect that 100 mg/kg b.w. The results were comparable
with the standard.
Table 3 shows the content of liver glycogen in liver tissues
of normal and experimental animals. There was interestingly
low content of glycogen during diabetes when compared to
the respective control group. Administration of EEMm, EECi
and glibenclamide tend to bring the level to near normal,cose level in STZ-diabetes in rats.
centration (mg/dL)
5th day 10th day 15th day
106.7 ± 1.9 104.50 ± 3.0 105.0 ± 3.5
378.3 ± 5.5a,# 390.17 ± 3.9a,# 403.3 ± 2.5a,#
328.5 ± 2.8b,* 270.0±5.4b,* 241.5 ± 4.1b,*
291.7 ± 5.3b,* 219.0 ± 5.8b,* 202.3 ± 4.0b,*
311.0 ± 3.1b,* 271.5 ± 2.4b,* 224.2 ± 4.9b,*
280.3 ± 4.6b,* 234.8 ± 4.9b,* 216.00 ± 3.6b,*
271.2 ± 7.4b,* 207.5 ± 3.7b,* 187.17 ± 2.8b,*
as injected to control and rest are treated groups.
Table 2 The effect on body weight changes during 14 days treatment of EEMm or EECi.
Groups Dose (mg/kg b.w.) Body weight (g/day)
0 day 5th day 10th day 15th day
Vehicle control – 208.2 ± 5.0 232.5 ± 6.9 248.2 ± 13.3 273.2 ± 9.1
STZ control – 180.7 ± 11.8a,# 179.3 ± 10.8a,# 173.2 ± 0a,# 168.0 ± 8.9a,#
EEMm 100 177.0 ± 7.9 183.5 ± 10.3 176.7 ± 8.8 175.8 ± 5.9
EEMm 200 181.3 ± 13.4 185.7 ± 13.4 190.7 ± 16.1b,* 195.8 ± 19.1b,***
EECi 100 185 ± 8.6 190.8 ± 9.2 174 ± 14.6 185.5 ± 8.3 b,*
EECi 200 179.8 ± 9.4 184.7 ± 9.2 191.7 ± 9.8b,* 199.5 ± 10.1b,***
Glibenclamide 0.5 181.7 ± 12.2 191.5 ± 6.6 203.5 ± 6.7b,*** 218.7 ± 5.4b,***
Body weight degreases with injection of STZ. Body weights were measure with 5 days interval for 15 days. Each value is the mean ± SEM;
n= 6.
a STZ induced diabetic group vs. vehicle control group.
b Treated group vs. STZ induced group.
# p< 0.001.
* p< 0.001.
*** p< 0.001.
Table 3 Effect of EEMm and EECi on liver glycogen level in STZ-diabetes in rats.
Groups Dose (mg/kg b.w.) Liver glycogen (mg/g of liver)
Vehicle control – 47.8 ± 1.8
STZ control – 15.2 ± 0.9a,#
EEMm 100 29.5 ± 1.8b,*
EEMm 200 33.8 ± 1.8b,*
EECi 100 27.5 ± 1.6b,*
EECi 200 32.6 ± 1.6b,*
Glibenclamide 0.5 38.7 ± 1.9b,*
Values are in mean ± SEM, 6 rats in each group. STZ (50 mg/kg b.w.) was injected to control and rest are treated groups.
a STZ induced diabetic group vs. vehicle control group.
b Treated group vs. STZ induced group.
# p< 0.001.
* p< 0.001.
Table 4 Effect of EEMm or EECi on biochemical parameter in STZ-diabetes in rats after 14 days treatment.
Groups Dose (mg/kg b.w.) Cholesterol (mg/dl) Triglycerides (mg/dl) LDL (mg/dl) HDL (mg/dl)
Vehicle control – 144.5 ± 1.34 114.3 ± 1.6 128.17 ± 1.11 53 ± 1.07
STZ control – 266.7 ± 2.4a,# 230.3 ± 1.8a,# 232.8 ± 2.8a,# 31.2 ± 1.2a,#
EEMm 100 196.7 ± 1.5b,* 175.33 ± 2.5b,* 173.3 ± 1.4b,* 34.7 ± 0.8
EEMm 200 165.5 ± 1.8b,* 149.50 ± 2.5b,* 144 ± 1.4b,* 42.7 ± 0.9b,*
EECi 100 203.0 ± 2.2b,* 183.5 ± 2.2b,* 177.8 ± 1.8b,* 33.7 ± 1.4
EECi 200 168.5 ± 1.9b,* 151.8 ± 1.3b,* 143 ± 1.6b,* 43.5 ± 1.0b,*
Glibenclamide 0.5 160.8 ± 1.6b,* 139.5 ± 1.3b,* 139 ± 1.2b,* 43.67 ± 0.9b,*
Values are mean ± SEM, 6 rats in each group. STZ (50 mg/kg b.w.) was injected to control and rest are treated groups.
a STZ induced diabetic group vs. normal group.
b Treated group vs. STZ induced diabetic group.
# p< 0.001.
* p< 0.001.
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gen in the drug treated diabetic animals.
Table 4 shows the concentration of concentration of TC,
TG, LDL and HDL. There was signiﬁcant increase in the con-
centration of TC, TG, and LDL and signiﬁcant decrease inHDL during diabetes when compared to corresponding con-
trol groups. Administration of EEMm, EECi and glibencla-
mide tend to bring the level to near normal.
Table 5 illustrates the effect of administration of EEMm,
EECi and glibenclamide on serum biochemical markers. The
Table 5 Effect of EEMm and EECi on serum biomarkers in STZ induced diabetes in rats after 14 days treatment.
Groups Dose (mg/kg b.w.) SGOT (l/L) SGPT (l/L) ALP (l/L)
Vehicle control – 62 ± 1.1 63.2 ± 1.1 124.2 ± 1.0
STZ control – 153 ± 1.4a,# 146.2 ± 1.2a,# 250.3 ± 1.1a,#
EEMm 100 99 ± 1.2 77.2 ± 1.4b,* 151.2 ± 4.0b,*
EEMm 200 63.2 ± 1.0b,* 66.2 ± 0.5b,* 126 ± 1.1b,*
EECi 100 97.8 ± 1.5 115.3 ± 0.9 178.2 ± 1.1
EECi 200 68.5 ± 1.7b,* 75.3 ± 1.2b,* 140.7 ± 1.2b,*
Glibenclamide 0.5 66.7 ± 1.2b,* 72.5 ± 1.2b,* 136.8 ± 1.6b,*
Values are mean ± SEM, 6 rats in each group. STZ (50 mg/kg b.w.) was injected to control and rest are treated groups.
a STZ induced diabetic group vs. normal group.
b Treated group vs. STZ induced diabetic group.
# p< 0.001.
* p< 0.001.
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creased in diabetes condition when compared with normal
control. Administration of EEMm, EECi and glibenclamide
was found to increase the levels near to normal values. The ef-
fect of EEMm at the dose of 200 mg/kg b.w. was more prom-
inent than glibenclamide.
5. Discussion
The traditional system of medicinal plants and practices have
been a imperative resource in many countries to control vari-
ous complications of diabetes mellitus as they are considered
to be less toxic and free from side effects than synthetic mole-
cules. Cucurbitaceae is one of the important families of the
plants with potent hypoglycemic effect (Bnouham et al.,
2006; Ghosh et al., 2004; Mukherjee et al., 1972) to be used
as best choice of alternative medicine for treating diabetes
throughout India. The current study dealt with two plants,
one is well known (C. indica) for antidiabetic activity and the
other is less known (M. maderaspatana).
The observed signiﬁcant increase in of blood glucose level in
diabetes rats could be due to the destruction of pancreatic b-cells
by STZ administration and decreased glycogen formation dur-
ing diabetes. The concurrent treatment of EEMm and EECi
for 14 days caused signiﬁcant reduction (p< 0.001) in blood
glucose level in STZ-diabetic rats and signiﬁcant increase in gly-
cogen formation. The increased content of glycogen in drug
treated experimental animals could be contributed to the de-
creased endogenous glucose output from the liver.
The priorities of lipid goals are LDL and non-HDL choles-
terol lowering, followed by HDL rising. The strong hypolipi-
demic activity observed in treatment with EEMm and EECi
could be through the control of hyperglycemia, as it is a major
determinant of TC, LDL and TG concentrations during diabe-
tes. The level of HDL-cholesterol, which increased after
administration of EEMm or EECi, might be due to the in-
crease in the activity of lecithin cholesterol acyl transferase,
which may contribute to the regulation of blood lipids.
The derangements of metabolic processes in disease are of-
ten associated with alteration in serum enzymatic activities.
Hence the assay of serum enzymes has become an important
goal during diabetes. The transaminase (SGOT, SGPT and
ALP) activity is increased in serum during diabetes (Ghosh
et al., 2004). The increased level in SGOT, SGPT and ALP,
which are active in the absence of insulin, with the availabilityof amino acids in blood of diabetics, are responsible for the in-
creased formation of gluconeogenesis and ketogenesis ob-
served in diabetics (Mukherjee et al., 1972).The remarkable
reduction in the level of SGOT, SGPT and ALP of treated dia-
betes rats could also contribute to reduction of glucose level by
inhibiting gluconeogenesis process. In the present study,
EEMm at the dose of 200 mg/kg b.w. was found to bring the
serum transaminase activity more signiﬁcantly than glibencla-
mide towards normal.
6. Conclusion
The plantM. maderaspatana is as effective as C. indica in treat-
ing the STZ-diabetic rats. Hence, this plant may be used as a
substitute for C. indica in treating diabetes. Combination of
these two plants in treating diabetes may be expected to pro-
duce better signiﬁcant results. However, further study is re-
quired to evaluate using a long term study and adverse and
beneﬁcial effects of their combination.
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